首页>
外文期刊>Biotechnology Law Report
>Lilly Entitled to Longer Protection of Raloxifene; Netherlands Removes Partial Patent Validity Law; Sanctionable Conduct Does Not Always Justify Award of Attorney Fees; Invitrogen–GE Healthcare Suit Sent to Texas; CAFC Rejects Appeal in HPV Case; Ariad, MIT Patent on Transcription Factor Fails Written Description Test; Motion for Summary Judgment of Non-Infringement Denied
【24h】
Lilly Entitled to Longer Protection of Raloxifene; Netherlands Removes Partial Patent Validity Law; Sanctionable Conduct Does Not Always Justify Award of Attorney Fees; Invitrogen–GE Healthcare Suit Sent to Texas; CAFC Rejects Appeal in HPV Case; Ariad, MIT Patent on Transcription Factor Fails Written Description Test; Motion for Summary Judgment of Non-Infringement Denied
展开▼
机译：礼来公司有权长期保护雷洛昔芬；荷兰取消部分专利有效性法；制裁行为并不总能证明授予律师费是合理的； Invitrogen – GE Healthcare诉讼已发送至德克萨斯； CAFC拒绝HPV案上诉；麻省理工学院Ariad的转录因子专利未通过书面描述测试；简易判决非侵权动议
